Effect of b-Adrenergic Antagonists on In-Hospital Mortality after XXXX .

@entity1 @entity64 @entity101 @entity955 @entity385
BACKGROUND: @entity385 accounts for 85%-90% of all @entity64 and currently has very limited therapeutic options. Recent studies of b-adrenergic antagonists suggest they may have neuroprotective effects that lead to improved functional outcomes in rodent models of @entity385 ; however, there are limited data in @entity1 . We aimed to determine whether there was an improvement in mortality rates among @entity1 who were taking b-blockers during the acute phase of their @entity385 . METHODS: A retrospective analysis of a prospectively collected database of @entity385 @entity1 was performed. @entity1 who were on b-adrenergic antagonists both at home and during the first 3 days of hospitalization were compared with @entity1 who were not on b-adrenergic antagonists to determine the association with @entity1 mortality rates. RESULTS: The study included a @entity1 population of 2804 @entity1 . In univariate analysis, use of b-adrenergic antagonists was associated with older age, @entity955 , @entity101 , and more-severe @entity64 . Despite this, multivariable analysis revealed a reduction in in-hospital mortality among @entity1 who were treated with b-adrenergic antagonists (odds ratio, .657; 95% confidence interval, .655-.658). CONCLUSIONS: The continuation of home b-adrenergic antagonist medication during the first 3 days of hospitalization after an @entity385 is associated with a decrease in @entity1 mortality. This supports the work done in rodent models suggesting neuroprotective effects of b-blockers after @entity385 .
